Q2 Holdings Aktie

Q2 Holdings für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1XEYE / ISIN: US74736L1098

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
06.08.2025 23:32:48

Immunome (IMNM) Q2 Revenue Surges 382%

Immunome (NASDAQ:IMNM), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share. GAAP revenue was well ahead of consensus. Overall, the period reflected significant cash investment and pipeline activity, but also highlighted the absence of commercial-stage products. Source: Analyst estimates for the quarter provided by FactSet. Immunome is focused on discovering and developing new targeted cancer treatments. The approach combines antibody-drug conjugates (ADCs)—targeted cancer drugs that deliver chemotherapy directly to cancer cells—and other modalities. The pipeline includes several investigational medicines, such as varegacestat for desmoid tumors, IM-1021 for solid tumors and blood cancers, and preclinical ADC candidates for various cancer types.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Q2 Holdings Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Immunome Inc Registered Shs 12,38 7,93% Immunome Inc Registered Shs
Q2 Holdings Inc 57,00 0,88% Q2 Holdings Inc